List of Amyvid drug patents
Amyvid is owned by Avid Radiopharms Inc.
Amyvid contains Florbetapir F-18.
Amyvid has a total of 2 drug patents out of which 0 drug patents have expired.
Amyvid was authorised for market use on 06 April, 2012.
Amyvid is available in solution;intravenous dosage forms.
Amyvid can be used as amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment.
The generics of Amyvid are possible to be released after 30 April, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(4 years from now) | |
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(4 years from now) | |
Drugs and Companies using FLORBETAPIR F-18 ingredient
Market Authorisation Date: 06 April, 2012
Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic